Cardiff Park Advisors’s VanEck Biotech ETF BBH Stock Holding History

Cardiff Park Advisors’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-35	Closed	-$6.58K	–	364
2026 Q1	$6.58K	Hold	35	–	–	﹤0.01%	362
2025 Q4	$6.62K	Hold	35	–	–	﹤0.01%	341
2025 Q3	$5.8K	Hold	35	–	–	﹤0.01%	372
2025 Q2	$5.37K	Hold	35	–	–	﹤0.01%	346
2025 Q1	$5.51K	Hold	35	–	–	﹤0.01%	342
2024 Q4	$5.49K	Hold	35	–	–	﹤0.01%	333
2024 Q3	$6.21K	Hold	35	–	–	﹤0.01%	332
2024 Q2	$5.89K	Hold	35	–	–	﹤0.01%	325
2024 Q1	$5.82K	Hold	35	–	–	﹤0.01%	342
2023 Q4	$5.79K	Buy	+35	New	+$5.39K	﹤0.01%	321
2022 Q4	–	Sell	-35	Closed	-$5K	–	312
2022 Q3	$5K	Buy	+35	New	+$5.29K	﹤0.01%	310

Other funds holding BBH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

MIM

Miller Investment Management West Conshohocken, Pennsylvania $1.09B AUM 18.31% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

CCA

Conservest Capital Advisors Wynnewood, Pennsylvania $1.26B AUM 24.75% 1-Year Est. Return

BFG

Bleakley Financial Group Fairfield, New Jersey $7.85B AUM 31.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Cardiff Park Advisors's BBH Position: Q2 2026 in Review

Cardiff Park Advisors sold out of VanEck Biotech ETF (BBH) in Q2 2026, closing a stake of 35 shares — an estimated $6.58K sold.

Cardiff Park Advisors first reported a position in BBH in Q3 2022 and held it in 11 quarters. The position peaked at $6.62K in Q4 2025. 110 funds tracked by Wall St. Rank hold BBH as of Q2 2026.

Cardiff Park Advisors reported no remaining VanEck Biotech ETF position as of Q2 2026 after selling out during the quarter.
Cardiff Park Advisors sold 35 VanEck Biotech ETF shares in Q2 2026, an estimated $6.58K.
Cardiff Park Advisors first reported a position in VanEck Biotech ETF in Q3 2022 and held it in 11 quarters.
Cardiff Park Advisors's VanEck Biotech ETF position peaked at $6.62K in Q4 2025.
110 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q2 2026.

Based on Cardiff Park Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.